Valganciclovir
- Atc Codes:J05AB14
- CAS Codes:175865-59-5#175865-60-8
- PHARMGKB ID:175865-59-5#175865-60-8
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Valcyte; Belgium: Valcyte; Bulgaria: Valcyte; Czech Republic: Valcyte; Denmark: Valcyte; Estonia: Valcyte; Finland: Valcyte; France: Rovalcyte; Germany: Valcyte; Hungary: Valcyte; Ireland: Valcyte; Italy: Darilin, Valcyte; Luxembourg: Valcyte; Netherlands: Valcyte, Valixa; Poland: Valcyte; Portugal: Valcyte; Spain: Valcyte; Sweden: Valcyte; UK: Valcyte.
North America
Canada: Valcyte; USA: Valcyte.
Latin America
Argentina: Valixa; Brazil: Valcyte; Mexico: Valcyte.
Asia
Japan: Valixa.
Drug combinations
Chemistry
Valganciclovir Hydrochloride: C~14~H~22~N~6~O~5~ HCl. Mw: 390.82. L-Valine, ester with 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine, monohydrochloride. CAS-175865-59-5; CAS-175865-60-8 (valganciclovir)(1997).
Pharmacologic Category
Antivirals; Nucleosides and Nucleotides. (ATC-Code: J05AB14).
Mechanism of action
Rapidly converted to ganciclovir in the body. Ganciclovir is phosphorylated to a substrate which competitively inhibits binding of deoxyguanosine triphosphate to DNA polymerase resulting in inhibition of viral DNA synthesis.
Therapeutic use
Treatment of cytomegalovirus retinitis in acquired immunodeficiency syndrome. Prevention of cytomegalovirus (CMV) disease in high-risk patients undergoing kidney, heart, or kidney/pancreas transplantation.
Pregnancy and lactiation implications
Converted to ganciclovir. Ganciclovir may adversely affect spermatogenesis and fertility (mutagenic potential). Contraindicated in nursing women.
Unlabeled use
Contraindications
Hypersensitivity to valganciclovir, ganciclovir, acyclovir, or any component of the formulation. Absolute neutrophil count <500/mm^3^. Platelet count <25000/mm^3^. Hemoglobin <8 g/dL.
Warnings and precautions
Hazardous agent. May cause granulocytopenia, anemia, and/or thrombocytopenia (use with caution in pre-existing bone marrow suppression, cytopenias, or in patients receiving myelosuppressive drugs/irradiation). Ganciclovir may adversely affect spermatogenesis and fertility. Use with caution in renal impairment. Not indicated for use in liver transplant patients (higher incidence of tissue-invasive CMV relative to oral ganciclovir).